Download PDF
Am J Perinatol 2021; 38(14): 1540-1546
DOI: 10.1055/s-0040-1713928
Original Article

Risk Factors for Respiratory Syncytial Virus Infections in Moderate/Late Premature Infants in Turkey: A Prospective Multicenter Epidemiological Study

Hilal Ozkan
1   Department of Neonatology, Faculty of Medicine, Uludag University, Bursa, Turkey
,
Solmaz Celebi
2   Department of Pediatric Infection, Faculty of Medicine, Uludag University, Bursa, Turkey
,
Nilgun Koksal
1   Department of Neonatology, Faculty of Medicine, Uludag University, Bursa, Turkey
,
Mustafa Hacımustafaoğlu
2   Department of Pediatric Infection, Faculty of Medicine, Uludag University, Bursa, Turkey
,
Esin Koc
3   Department of Neonatology, Faculty of Medicine, Gazi University, Ankara, Turkey
,
Hasan Tezer
4   Department of Pediatric Infection, Faculty of Medicine, Gazi University, Ankara, Turkey
,
Merih Cetinkaya
5   Department of Neonatology, Kanuni Sultan Suleyman Training and Research Hospital, Istanbul, Turkey
,
Burcu Cebeci
6   Department of Neonatology, Faculty of Medicine, Ankara University, Ankara, Turkey
,
Omer Erdeve
7   Department of Pediatric Infection, Faculty of Medicine, Ankara University, Ankara, Turkey
,
Halil Ozdemir
7   Department of Pediatric Infection, Faculty of Medicine, Ankara University, Ankara, Turkey
,
Turkish Neonatal Society RSV Study Group Turkish Pediatric Infectious Disease Society RSV Study Group › Author Affiliations
› Further Information
Also available at
    Permissions and Reprints

Corrected by:

Erratum: Risk Factors for Respiratory Syncytial Virus Infections in Moderate/Late Premature Infants in Turkey: A Prospective Multicenter Epidemiological StudyAm J Perinatol 2021; 38(14): e1-e1
DOI: 10.1055/s-0040-1715642

Abstract

Objective Respiratory syncytial virus (RSV) is one of the most prevalent causes of lower respiratory tract infection (LRTI). The primary objective of this study is to provide the risk modelling of confirmed RSV infection in children who were born preterm at 29 to 35 weeks of gestational age and presented with LRTI.

Study Design This prospective, multicenter study was performed between October 2015 and March 2017. Premature infants born with gestational age between 29 and 35 weeks that were ≤2 years of age at the beginning of the RSV season and admitted to the hospital with clinical findings of LRTI during the season were included. RSV-positive and -negative infants were compared in terms of demographic features, risk factors, and requirement of hospitalization.

Results RSV positive group was lower than RSV negative group and ratio of ≤3 months age at admission was significant higher in RSV (+) group. RSV-positive infants were found to be significantly born during or 3 months prior to RSV season. The rate and duration of hospitalization and need for mechanical ventilation were significantly higher in RSV positive infants. The rate and duration of hospitalization in RSV positive patients was related to the chronological age.

Conclusion This study showed that preterm infants with RSV-associated LRTI significantly needed more hospitalization, intensive care admission, and mechanical ventilation. In addition need of hospitalization and duration of hospitalization were significant higher in ≤3 months of age. Therefore, we suggest the importance of palivizumab prophylaxis in infants ≤ 3 months chronological age, especially during the RSV season.

Keywords

premature - respiratory syncytial virus - lower tract infection - hospitalization

* List of Turkish Neonatal Society RSV Study Group collaborators are provided in [Supplementary Material] (available in the online version).


** List of Turkish Pediatric Infectious Disease Society RSV Study Group collaborators are provided in [Supplementary Material] (available in the online version).


Supplementary Material



Publication History

Received: 02 December 2019

Accepted: 03 June 2020

Article published online:
13 July 2020

© 2020. Thieme. All rights reserved.

Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA

 

  • References

  • 1 Alvarez AE, Marson FA, Bertuzzo CS, Arns CW, Ribeiro JD. Epidemiological and genetic characteristics associated with the severity of acute viral bronchiolitis by respiratory syncytial virus. J Pediatr (Rio J) 2013; 89 (06) 531-543
    CrossrefPubMedGoogle Scholar
  • 2 Nair H, Nokes DJ, Gessner BD. et al. Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis. Lancet 2010; 375 (9725): 1545-1555
    CrossrefPubMedGoogle Scholar
  • 3 Ambrose CS, Anderson EJ, Simões EA. et al. Respiratory syncytial virus disease in preterm infants in the U.S. born at 32-35 weeks gestation not receiving immunoprophylaxis. Pediatr Infect Dis J 2014; 33 (06) 576-582
    CrossrefPubMedGoogle Scholar
  • 4 American Academy of Pediatrics Committee on Infectious Diseases, American Academy of Pediatrics Bronchiolitis Guidelines Committee. Updated guidance for palivizumab prophylaxis among infants and young children at increased risk of hospitalization for respiratory syncytial virus infection. Pediatrics 2014; 134 (02) 415-420
    CrossrefPubMedGoogle Scholar
  • 5 American Academy of Pediatrics Committee on Infectious Diseases, American Academy of Pediatrics Bronchiolitis Guidelines Committee. Updated guidance for palivizumab prophylaxis among infants and young children at increased risk of hospitalization for respiratory syncytial virus infection. Pediatrics 2014; 134: 620-638
    CrossrefPubMedGoogle Scholar
  • 6 Blanken MO, Koffijberg H, Nibbelke EE, Rovers MM, Bont L, Dutch RSV. Neonatal Network. Prospective validation of a prognostic model for respiratory syncytial virus bronchiolitis in late pre-term infants: a multicentre birth cohorts study. PLoS One 2013; 8: e59161
    CrossrefPubMedGoogle Scholar
  • 7 Law BJ, Langley JM, Allen U. et al. The Pediatric Investigators Collaborative Network on Infections in Canada study of predictors of hospitalization for respiratory syncytial virus infection for infants born at 33 through 35 completed weeks of gestation. Pediatr Infect Dis J 2004; 23 (09) 806-814
    CrossrefPubMedGoogle Scholar
  • 8 Figueras-Aloy J, Carbonell-Estrany X, Quero-Jiménez J. et al; IRIS Study Group. FLIP-2 Study: risk factors linked to respiratory syncytial virus infection requiring hospitalization in premature infants born in Spain at a gestational age of 32 to 35 weeks. Pediatr Infect Dis J 2008; 27 (09) 788-793
    CrossrefPubMedGoogle Scholar
  • 9 Horn SD, Smout RJ. Effect of prematurity on respiratory syncytial virus hospital resource use and outcomes. J Pediatr 2003; 143 (5, Suppl): S133-S141
    CrossrefPubMedGoogle Scholar
  • 10 Gijtenbeek RG, Kerstjens JM, Reijneveld SA, Duiverman EJ, Bos AF, Vrijlandt EJ. RSV infection among children born moderately preterm in a community-based cohort. Eur J Pediatr 2015; 174 (04) 435-442
    CrossrefPubMedGoogle Scholar
  • 11 Helfrich AM, Nylund CM, Eberly MD, Eide MB, Stagliano DR. Healthy Late-preterm infants born 33-36+6 weeks gestational age have higher risk for respiratory syncytial virus hospitalization. Early Hum Dev 2015; 91 (09) 541-546
    CrossrefPubMedGoogle Scholar
  • 12 Kanra G, Tezcan S, Yilmaz G. Turkish National Respiratory Syncytial Virus (RSV) Team. Respiratory syncytial virus epidemiology in Turkey. Turk J Pediatr 2005; 47 (04) 303-308
    PubMedGoogle Scholar
  • 13 Gülen F, Yıldız B, Çiçek C, Demir E, Tanaç R. Ten year retrospective evaluation of the seasonal distribution of agent viruses in childhood respiratory tract infections. Turk Pediatri Ars 2014; 49 (01) 42-46
    CrossrefPubMedGoogle Scholar
  • 14 Gregson D, Lloyd T, Buchan S, Church D. Comparison of the RSV respi-strip with direct fluorescent-antigen detection for diagnosis of respiratory syncytial virus infection in pediatric patients. J Clin Microbiol 2005; 43 (11) 5782-5783
    CrossrefPubMedGoogle Scholar
  • 15 Alan S, Erdeve O, Cakir U. et al; TurkNICU-RSV Trial Group. Outcome of the respiratory syncytial virus related acute lower respiratory tract infection among hospitalized newborns: a prospective multicenter study. J Matern Fetal Neonatal Med 2016; 29 (13) 2186-2193
    CrossrefPubMedGoogle Scholar
  • 16 Oncel MY, Arayici S, Simsek GK. et al. Risk factors for hospitalization due to lower respiratory tract infection in preterm infants on palivizumab prophylaxis. Iran J Pediatr 2013; 23 (06) 693-700
    PubMedGoogle Scholar
  • 17 Hacımustafaoğlu M, Celebi S, Bozdemir SE. et al. RSV frequency in children below 2 years hospitalized for lower respiratory tract infections. Turk J Pediatr 2013; 55 (02) 130-139
    PubMedGoogle Scholar
  • 18 Turkish Neonatal Society. The seasonal variations of respiratory syncytial virus infections in Turkey: a 2-year epidemiological study. Turk J Pediatr 2012; 54 (03) 216-222
    PubMedGoogle Scholar
  • 19 Silvestri M, Marando F, Costanzo AM, di Luzio Paparatti U, Rossi GA. Respiratory Syncytial Virus-associated hospitalization in premature infants who did not receive palivizumab prophylaxis in Italy: a retrospective analysis from the Osservatorio Study. Ital J Pediatr 2016; 42: 40
    CrossrefPubMedGoogle Scholar
  • 20 Figueras Aloy J, Carbonell Estrany X. Comité de Estándares de la SENeo. Actualización de las recomendaciones de la Sociedad Española de Neonatología para la utilización del palivizumab como profilaxis de las infecciones graves por el virus respiratorio sincitial. An Pediatr (Barc) 2015; 199: 1-2
    PubMedGoogle Scholar
  • 21 Bollani L, Baraldi E, Chirico G. et al; Italian Society of Neonatology. Revised recommendations concerning palivizumab prophylaxis for respiratory syncytial virus (RSV). Ital J Pediatr 2015; 41: 97
    CrossrefPubMedGoogle Scholar
  • 22 Paes B. Respiratory syncytial virus in otherwise healthy prematurely born infants: a forgotten majority. Am J Perinatol 2018; 35 (06) 541-544
    Article in Thieme ConnectPubMedGoogle Scholar
  • 23 Capizzi A, Silvestri M, Orsi A, Cutrera R, Rossi GA, Sacco O. The impact of the recent AAP changes in palivizumab authorization on RSV-induced bronchiolitis severity and incidence. Ital J Pediatr 2017; 43 (01) 71
    CrossrefPubMedGoogle Scholar
  • 24 Kong AM, Krilov LR, Fergie J. et al. The 2014-2015 National Impact of the 2014 American Academy of Pediatrics Guidance for Respiratory Syncytial Virus Immunoprophylaxis on Preterm Infants Born in the United States. Am J Perinatol 2018; 35 (02) 192-200
    Article in Thieme ConnectPubMedGoogle Scholar
  • 25 Cetinkaya M, Oral TK, Karatekin S, Cebeci B, Babayigit A, Yesil Y. Efficacy of palivizumab prophylaxis on the frequency of RSV-associated lower respiratory tract infections in preterm infants: determination of the ideal target population for prophylaxis. Eur J Clin Microbiol Infect Dis 2017; 36 (09) 1629-1634
    CrossrefPubMedGoogle Scholar
  • 26 Anderson EJ, Krilov LR, DeVincenzo JP. et al. SENTINEL1: an observational study of respiratory syncytial virus hospitalizations among U.S. Infants born at 29 to 35 weeks' gestational age not receiving immunoprophylaxis. Am J Perinatol 2017; 34 (01) 51-61
    Article in Thieme ConnectPubMedGoogle Scholar
  • 27 Hall CB, Weinberg GA, Blumkin AK. et al. Respiratory syncytial virus-associated hospitalizations among children less than 24 months of age. Pediatrics 2013; 132 (02) e341-e348
    CrossrefPubMedGoogle Scholar
  • 28 Straňák Z, Saliba E, Kosma P. et al. Predictors of RSV LRTI hospitalization in infants born at 33 to 35 weeks gestational age: a large multinational study (PONI). PLoS One 2016; 11 (06) e0157446
    CrossrefPubMedGoogle Scholar
  • 29 Anderson EJ, Krilov LR, DeVincenzo JP. et al. SENTINEL1: two-season study of respiratory syncytial virus hospitalizations among u.s. infants born at 29 to 35 weeks' gestationalage not receiving immunoprophylaxis. Am J Perinatol 2020; 37 (04) 421-429
    Article in Thieme ConnectPubMedGoogle Scholar
  • 30 Hervás D, Reina J, Yañez A, del Valle JM, Figuerola J, Hervás JA. Epidemiology of hospitalization for acute bronchiolitis in children: differences between RSV and non-RSV bronchiolitis. Eur J Clin Microbiol Infect Dis 2012; 31 (08) 1975-1981
    CrossrefPubMedGoogle Scholar
  • 31 Blanken MO, Paes B, Anderson EJ. et al. Risk scoring tool to predict respiratory syncytial virus hospitalisation in premature infants. Pediatr Pulmonol 2018; 53 (05) 605-612
    CrossrefPubMedGoogle Scholar